Introduction to Bacterial Meningitis
(Designed Specifically for PEBC Exam Preparation)
This chapter presents an in-depth exploration of bacterial meningitis, a critical condition that requires pharmacists to understand its anatomy, pathophysiology, and clinical management. Prepared with a focus on the Pharmacy Examining Board of Canada (PEBC) exams, this content emphasizes the foundational and practical knowledge necessary for candidates to excel, while also aligning with the clinical realities of Canadian pharmacy practice.
Anatomy & OverviewMeningitis refers to the inflammation of the cranial and spinal leptomeninges, which are the three protective layers surrounding the brain and spinal cord:
Dura Mater: The outermost layer, tightly adherent to the cranial periosteum.
Arachnoid Mater: The middle layer, which loosely envelopes the brain and spinal cord.
Pia Mater: The innermost layer, intimately connected with the surface of the brain and spinal cord.
The cerebrospinal fluid (CSF), located in the subarachnoid space between the arachnoid and pia mater, plays a pivotal role in maintaining homeostasis and protecting the central nervous system (CNS). Understanding this anatomy is essential for grasping the pathophysiology of bacterial meningitis, as this infection primarily affects the CSF and surrounding tissues.
This chapter is dedicated to bacterial meningitis, excluding other conditions like encephalitis, brain abscesses, or meningitis of non-bacterial origin (e.g., viral, fungal, or parasitic causes). It also does not address conditions like ventriculitis or meningitis linked to ventricular shunts. Drug-induced and carcinomatous meningitis are similarly outside the scope of this discussion.
Etiology and Common Pathogens
The leading bacterial pathogens responsible for meningitis are organisms commonly found colonizing the mucosal surfaces of the respiratory tract, including:
Streptococcus pneumoniae
Neisseria meningitidis
Haemophilus influenzae
For instance, colonization of the nasopharynx by these pathogens can reach rates as high as 40% during or following a respiratory viral illness, particularly in children. These bacteria use specialized structures, such as fimbriae or pili, to adhere to mucosal epithelial cells. Viral infections often upregulate host cell receptors, enhancing bacterial adherence.
Other pathogens, such as Listeria monocytogenes and Group B Streptococcus, originate from the gastrointestinal or genitourinary tract, demonstrating the diverse routes by which bacterial meningitis can develop.
Pathogenesis
After colonizing the mucosa, bacteria may breach the mucosal barrier, entering the bloodstream through or between epithelial cells. Once in the bloodstream, the bacteria can cross the blood-brain barrier, often through the choroid plexus, to invade the CNS. Experimental evidence suggests that higher bacterial loads in the bloodstream correlate with an increased likelihood of meningitis.
Direct extension from infections like otitis media, sinusitis, or, less commonly, structural defects such as those in the cribriform plate, can also lead to bacterial invasion of the CNS.
Host Immune Response and Inflammatory Cascade
Within the subarachnoid space, host defenses are minimal, allowing rapid bacterial multiplication. This triggers a cascade of inflammatory responses mediated by cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1β). Ironically, these inflammatory processes can exacerbate the condition by increasing granulocyte influx, intensifying inflammation, and causing neuronal damage.
The combined effects of inflammation, oxidative stress, and bacterial toxins can result in long-term complications such as central nervous system injury and hearing loss. Understanding these mechanisms is crucial for pharmacists to appreciate the importance of early and effective therapeutic interventions.
Focus of This Chapter
The aim of this chapter is to equip PEBC candidates with the essential knowledge required to address bacterial meningitis in clinical practice. Through detailed discussion, it highlights:
The anatomical and physiological considerations relevant to the infection.
The pathophysiology underlying disease progression.
The most common bacterial etiologies and their modes of transmission.
The immune response and its role in disease severity and complications.
Goals of Therapy
When a clinical diagnosis of meningitis is suspected, it is critical to establish therapeutic objectives that address the immediate and long-term needs of the patient. These goals include:
Initiating Prompt Empiric Therapy: Start antibiotic treatment with drugs capable of penetrating the central nervous system (CNS) immediately after meningitis is suspected, even before a specific pathogen is identified.
Tailoring Therapy: Modify the antibiotic regimen based on culture results or pathogen identification to ensure targeted and effective treatment.
Eradicating Bacteria: Eliminate the bacterial infection from the CNS completely to prevent further spread or recurrence.
Reducing Morbidity and Mortality: Implement timely and appropriate interventions to minimize the risk of severe complications and death associated with bacterial meningitis.
Preventing Acute and Chronic Complications: Actively manage and mitigate the risk of neurological damage, hearing loss, or other long-term sequelae arising from the disease.
Investigations
Timely assessment and investigation are crucial for the effective management of bacterial meningitis. Evaluations should be conducted in an acute care or inpatient facility equipped with laboratory and imaging capabilities. Decisions regarding diagnostic tests and treatments must prioritize clinical urgency while being supported by laboratory findings.
Key Considerations:
Clinical presentation varies based on patient age, ability to communicate symptoms, and stage of infection.
While clinical prediction models may help differentiate bacterial meningitis from viral causes, initiating empiric antibiotics is often based on clinical judgment.
Investigations should not delay the start of empiric treatment, especially when clinical signs strongly suggest bacterial meningitis.
History and Clinical Presentation
Risk Factors
Extremes of Age:
Elderly Individuals (>60 years): Aging weakens the immune system, making elderly people more prone to infections like bacterial meningitis.
Young Children (<5 years): The risk is particularly high in infants and neonates due to their immature immune systems and increased vulnerability to infections.
Crowded Living Conditions:
Military Recruits: Prolonged close-contact settings can facilitate the transmission of respiratory pathogens.
Dormitories: Crowded environments such as student dormitories create a higher risk of pathogen exposure, particularly for meningococcus (N. meningitidis).
Exposure to Pathogens
Recent Colonization: Acquisition of bacterial colonization in the nasopharynx can predispose individuals to invasive infections.
Close Contact with a Meningitis Patient: Direct exposure to an infected individual’s respiratory secretions significantly increases the risk of bacterial meningitis.
Contiguous Infections: Infections in nearby anatomical areas, such as sinusitis, otitis media, and mastoiditis, can spread to the central nervous system (CNS).
Intravenous Drug Abuse: Increases exposure to bloodstream infections that can potentially seed the meninges.
Bacterial Endocarditis (Infective Endocarditis): A condition where bacteria in the bloodstream can travel to the meninges and lead to bacterial meningitis.
Dural Defects: Individuals with a history of neurosurgery, CNS trauma, or congenital defects have compromised meninges, increasing the risk of bacterial invasion.
CNS Devices: The presence of devices such as ventriculoperitoneal (VP) shunts or other CNS implants heightens the risk of infection.
Cochlear Implants: Individuals with cochlear implants are 30 times more likely to develop meningitis compared to the general population.
Immunosuppression: Impairment of the immune system significantly increases the risk of bacterial meningitis. Key factors include:
Metabolic Disorders: Conditions like diabetes or cirrhosis due to alcoholism compromise immune responses, leading to increased susceptibility.
HIV: Individuals with HIV have impaired immunity, increasing the risk of opportunistic infections, including meningitis.
Immunosuppressive Therapies: Treatment with immunosuppressive drugs, such as steroids or chemotherapy, reduces the ability to fight infections.
Splenectomy (Removal of the Spleen): The spleen plays a critical role in defending against encapsulated bacteria like S. pneumoniae and N. meningitidis. Post-splenectomy patients are at a significantly higher risk.
Hematologic Disorders:Disorders like sickle cell disease and thalassemia major compromise immune function, increasing the risk of invasive bacterial infections.
Malignancies: Cancer weakens the immune system, either directly or through treatment regimens, making bacterial meningitis more likely.
Clinical Symptoms by Age Group
Infants and Young Children (<2 years): Symptoms may be non-specific, including fever or hypothermia, irritability, lethargy, poor feeding, vomiting, seizures, or bulging fontanelle (a late sign).
Older Children and Adults: Fever, headache, stiff neck, photophobia, and systemic unwellness (e.g., vomiting). Neurological symptoms may include confusion, altered consciousness, or focal deficits.
Severe Cases: Patients may present with septic shock, characterized by low blood pressure, poor perfusion, and decreased consciousness.
Physical Examination Findings
General Findings
Vital Signs: Tachycardia and tachypnea are common; hypotension may be seen in septic shock.
Meningeal Signs: Stiff neck, Kernig's, and Brudzinski's signs may be absent in infants or atypical presentations.
Neurological Signs
Inability to walk, confusion, cranial nerve palsies, and other indications of increased intracranial pressure (e.g., papilledema).
Petechiae or purpura suggestive of meningococcal meningitis may be observed.
Laboratory Investigations
Cerebrospinal Fluid (CSF)
Key Tests: Perform lumbar puncture (LP) to analyze CSF for cell counts, glucose, protein levels, and culture.
Findings in Bacterial Meningitis:
Elevated white blood cell (WBC) count (>100 × 10⁶/L, predominantly neutrophils).
Reduced CSF glucose relative to blood glucose.
Elevated CSF protein and lactate levels.
Positive Gram stain in 80–90% of cases (less likely if antimicrobials were started).
Additional Tests
Blood cultures to detect bacteremia.
Imaging (CT or MRI) if focal neurological signs, altered consciousness, or signs of herniation are present.
Imaging Considerations
Neuroimaging is not routinely required but is recommended in specific situations:
When raised intracranial pressure or focal neurological signs are suspected.
For older adults or immunosuppressed patients, where imaging may reveal complications like cerebritis.
Ensure that imaging does not delay the administration of empiric antimicrobials. In such cases, proceed with blood cultures and antibiotic therapy while awaiting imaging results.
Therapeutic Choices
Effective treatment of bacterial meningitis requires timely and appropriate therapeutic interventions to address the infection and mitigate complications. The following outlines the principles of therapy and specific pharmacologic choices designed to ensure comprehensive patient management.
Principles of Antibacterial Therapy
Timely Administration:
Antibiotic therapy should begin immediately upon clinical suspicion of meningitis. Early treatment is crucial, as each hour of delay can increase the risk of death or disability by up to 30% in adults.
Initiate empiric therapy to target the most common pathogens in the patient’s age group and clinical context, as the causative organism is often unknown at presentation.
Empiric Therapy:
The choice of empiric antibiotics depends on the likely causative organisms, patient age, comorbidities, and local antimicrobial resistance patterns (see Table 1 for age-specific pathogens).
Combination therapy is common to ensure broad coverage. For example:
In neonates (<1 month), use cefotaxime, ampicillin, and gentamicin to cover Group B Streptococcus (GBS) and E. coli.
In patients >1 month, ceftriaxone or cefotaxime is recommended with vancomycin for coverage of S. pneumoniae, N. meningitidis, and H. influenzae.
In individuals >60 years or those with risk factors for Listeria monocytogenes (e.g., immunosuppression), add ampicillin.
Adjunctive Recommendations:
Administer a cephalosporin before vancomycin (with a 2-hour gap) to maximize initial CSF penetration.
For trauma-related cases or potential soil contamination, include ceftazidime for Pseudomonas coverage and consider amphotericin B for fungal infections.
Culture-Directed Therapy:
Modify therapy based on Gram stain, culture, and sensitivity results (see Table 2 for specific guidelines).
For instance, if S. pneumoniae with low penicillin MIC is isolated, penicillin G may be used; higher MICs require ceftriaxone or cefotaxime, and resistant strains may necessitate vancomycin ± rifampin.
Monitoring and Adjustments:
Discontinue vancomycin if cultures are negative or if pathogens are susceptible to penicillin or cephalosporins.
Address any potential drug interactions, adverse effects, or infusion-related reactions (e.g., vancomycin flushing syndrome).
Managing Drug Allergies:
In cases of severe penicillin allergy, assess risks and benefits of alternative treatments. Ceftriaxone may still be used due to negligible cross-reactivity, with precautions for anaphylaxis. Desensitization is an option if necessary but may delay treatment.
For rare resistance to standard antibiotics, options like moxifloxacin or meropenem may be considered, though these are not first-line treatments.
Neonates (<1 month):
Empiric therapy: Cefotaxime + Ampicillin + Gentamicin for broad coverage of pathogens such as GBS and E. coli.
If Gram-positive cocci (GBS) are identified, cefotaxime may not be needed.
Infants and Children (>1 month): Use ceftriaxone or cefotaxime combined with vancomycin to cover major pathogens like S. pneumoniae, N. meningitidis, and H. influenzae.
Elderly or Immunocompromised Patients (>60 years): Add ampicillin to standard therapy to cover Listeria monocytogenes.
Trauma or Soil Contamination: Include ceftazidime for Pseudomonas coverage and consider fungal treatment with amphotericin B if contamination is suspected.
Penicillin-Resistant Pneumococcus: For strains resistant to penicillin and cephalosporins, add vancomycin and consider rifampin for enhanced CSF penetration. Infectious disease consultation is recommended.
Duration of Therapy:
The length of treatment depends on the pathogen and patient-specific factors. For example, N. meningitidis infections may require 7 days, while S. pneumoniae or Listeria typically require 10–14 days.
Complications or slow recovery may extend therapy duration.
Negative Cultures:
If cultures are negative but bacterial meningitis is still suspected, treatment should continue based on clinical findings. Molecular tests like PCR can assist in pathogen identification.
Adjunct Therapy with Dexamethasone: If resistant S. pneumoniae is detected and dexamethasone was used, strongly consider adding rifampin to improve bacterial eradication in the CSF.
Important Safety Considerations
Meropenem vs. Imipenem: While meropenem is an option for meningitis, imipenem is not recommended due to a higher seizure risk.
Vancomycin Infusion Reactions: Administer vancomycin slowly to avoid flushing syndrome caused by histamine release.
Bacterial Meningitis: Empiric Therapy Based on Age and Risk Factors
1. Infants (<1 month)
Common Pathogens:
Streptococcus agalactiae (Group B Streptococcus)
Escherichia coli
Other Enterobacteriaceae
Listeria monocytogenes (rare)
Empiric Antibacterial Regimen:
Ampicillin + Cefotaxime
Cefotaxime is preferred over ceftriaxone in neonates to avoid bilirubin displacement from albumin and the potential risk of hyperbilirubinemia.
Add gentamicin if early neonatal meningitis is suspected to enhance synergy for Group B Streptococcal infections.
If Gram-negative bacilli are identified on CSF Gram stain, consider meropenem as an alternative.
2. Children (≥1 month)
Common Pathogens:
Streptococcus pneumoniae
Neisseria meningitidis
S. agalactiae (Group B Streptococcus)
Haemophilus influenzae type b (rare since universal vaccination)
Escherichia coli
Other Enterobacteriaceae (rare)
Empiric Antibacterial Regimen:
Ceftriaxone or Cefotaxime ± Vancomycin
Vancomycin provides coverage for penicillin-resistant S. pneumoniae if local resistance patterns suggest reduced susceptibility.
3. Adults (No Specific Health Conditions)
Common Pathogens:
S. pneumoniae
N. meningitidis
H. influenzae type a
Aerobic Gram-negative bacilli (rare)
Empiric Antibacterial Regimen:
Ceftriaxone or Cefotaxime ± Vancomycin
4. Adults with Risk Factors
Risk Factors:
Age >60 years
Immunosuppression (e.g., chemotherapy, HIV, pregnancy)
Biologic therapy exposure (e.g., eculizumab)
Malignancy or organ transplantation
Alcohol use disorder
Brainstem involvement on imaging
Common Pathogens:
S. pneumoniae
N. meningitidis
H. influenzae type b
Listeria monocytogenes
Empiric Antibacterial Regimen:
Ceftriaxone or Cefotaxime + Ampicillin ± Vancomycin
Ampicillin is added for coverage of Listeria monocytogenes.
5. Patients with CSF Leaks, VP Shunts, or Head Trauma
Risk Factors:
Cerebrospinal fluid (CSF) leaks or skull fractures
Ventriculoperitoneal (VP) shunts
Penetrating head trauma
Common Pathogens:
Staphylococcus epidermidis
S. aureus
S. pneumoniae
N. meningitidis
H. influenzae type a, b, or nontypeable
Aerobic Enterobacteriaceae
Pseudomonas species
Empiric Antibacterial Regimen:
Ceftriaxone or Cefotaxime ± Vancomycin
For soil contamination: Replace cefotaxime with ceftazidime for Pseudomonas coverage and consider adding amphotericin B for fungal infections (e.g., Aspergillus).
Additional Notes
Cefotaxime vs. Ceftriaxone in Neonates: Cefotaxime is preferred for neonates to avoid the risk of bilirubin displacement from albumin, which could lead to hyperbilirubinemia.
Vancomycin Administration: Administer vancomycin 2 hours after ceftriaxone or cefotaxime to ensure initial broad coverage and better CSF penetration.
Vaccination Impact: H. influenzae type b infections have become rare due to widespread vaccination.
Specific Risk Factors: Tailor antibiotic therapy to patient-specific risk factors and pathogens, as indicated in the table.
Pathogen-Specific Antibacterial Regimens
1. Streptococcus pneumoniae
Susceptible to Penicillin:
First Line: Penicillin G
Alternative: Ceftriaxone or Cefotaxime
Duration: 10 days
Intermediate or Resistant to Penicillin:
First Line: Ceftriaxone or Cefotaxime (consult ID specialist)
Alternative: Meropenem
Duration: 10 days
Non-Susceptible to Penicillin & Ceftriaxone/Cefotaxime:
First Line: High-dose Ceftriaxone/Cefotaxime + Vancomycin ± Rifampin (consult ID specialist)
Alternative: Meropenem
Duration: 14 days
2. Neisseria meningitidis
Susceptible to Penicillin:
First Line: Penicillin G
Alternative: Ceftriaxone or Cefotaxime
Duration: 7 days
Non-Susceptible to Penicillin:
First Line: Ceftriaxone or Cefotaxime
Alternative: Meropenem (consult ID specialist)
Duration: 7 days
3. Haemophilus influenzae
Beta-Lactamase Negative:
First Line: Ampicillin
Alternative: Ceftriaxone or Cefotaxime
Duration: 10 days
Beta-Lactamase Positive:
First Line: Ceftriaxone or Cefotaxime
Alternative: Consult ID specialist
Duration: 10 days
4. Group B Streptococcus (Streptococcus agalactiae)
First Line: Penicillin G + Gentamicin or Tobramycin for 5–7 days
Alternative: Ampicillin or Ceftriaxone
Duration: 14–21 days
5. Listeria monocytogenes
First Line: Ampicillin + Gentamicin or Tobramycin for 3–7 days
Alternative: Sulfamethoxazole/Trimethoprim
Duration: ≥21 days
6. Enterobacteriaceae
First Line: Ceftriaxone or Cefotaxime + Gentamicin or Tobramycin
Alternative: Meropenem (consult ID specialist)
Duration: 21 days
Key Notes
Duration of Therapy: Varies based on the pathogen; some cases may require longer therapy.
Combination Therapy: Gentamicin or tobramycin may be added for synergy and is typically administered for 3–7 days.
Consult ID Specialist: Recommended for resistant pathogens or alternative therapies.
Pediatric Considerations: Use gentamicin or tobramycin in adults only if Pseudomonas is suspected.
Adjunctive Corticosteroids in Bacterial Meningitis
Adjunctive corticosteroid therapy is used to reduce inflammation in the central nervous system (CNS) caused by bacterial meningitis. This inflammation, if left unchecked, can lead to severe neurologic complications, such as hearing loss, strokes, blindness, cognitive impairment, and thrombosis as a late sequela. To maximize efficacy, corticosteroids should be administered either before or concurrently with the first dose of antibiotics. The benefits of corticosteroid therapy are most evident in cases of Haemophilus influenzae type b meningitis in children and Streptococcus pneumoniae meningitis in adults. However, they do not appear to be effective in meningitis caused by other pathogens, such as Listeria monocytogenes.
Potential Concerns
Delayed Sterilization of CSF: Corticosteroids, particularly dexamethasone, may reduce CSF drug penetration when vancomycin is used to treat resistant S. pneumoniae. Although this is a theoretical risk, it underscores the importance of adding rifampin to the regimen in such cases.
Adjunctive Corticosteroids in Children
Benefits:
Meta-analyses show significant benefits in reducing severe hearing loss in children with H. influenzae type b meningitis.
For S. pneumoniae-associated meningitis, corticosteroids provide a trend toward reducing hearing loss, particularly when administered before or with the first dose of antibiotics.
Effect on Mortality: Studies indicate no significant difference in mortality rates among infants and children treated with corticosteroids.
Recommendations:
When to Consider: Adjunctive dexamethasone may be considered in children >4 weeks old with community-acquired bacterial meningitis, especially if H. influenzae or S. pneumoniae is suspected.
Dosage: 0.6 mg/kg/day in 4 divided doses for 2 days.
Discontinuation: Stop corticosteroids if cultures do not identify H. influenzae or S. pneumoniae.
Adjunctive Corticosteroids in Adults
Benefits:
In high-income countries, corticosteroids have been shown to reduce short-term neurologic complications and hearing loss in bacterial meningitis.
However, their effect on mortality and long-term neurologic disability remains unclear, with no significant benefits observed in resource-poor settings.
Risks:
Corticosteroids are not recommended when Listeria is suspected. Studies suggest worse outcomes in patients with neurolisteriosis treated with corticosteroids.
Discontinue corticosteroids if Listeria is confirmed.
Recommendations:
When to Use: Dexamethasone is recommended initially in adults with community-acquired bacterial meningitis, particularly when S. pneumoniae or H. influenzae is suspected.
Dosage:
Commonly used: 10 mg every 6 hours for 4 days.
IDSA Guidelines: 0.15 mg/kg every 6 hours for 2–4 days, starting before or with the first dose of antibiotics.
Discontinuation: Stop corticosteroids if cultures do not identify H. influenzae or S. pneumoniae.
Summary of Recommendations
Pathogen-Specific Considerations: Benefits are seen primarily in H. influenzae type b and S. pneumoniae meningitis, while corticosteroids should be avoided in suspected or confirmed Listeria monocytogenes cases.
Timing: Start corticosteroids before or with the first dose of antibiotics for maximum benefit.
Duration: Continue therapy for 2–4 days unless cultures indicate pathogens unlikely to benefit from corticosteroid use.
Prevention of Bacterial Meningitis
Vaccination
Vaccines are the cornerstone of bacterial meningitis prevention, and their implementation has significantly reduced disease rates both in Canada and globally. The key vaccines include those targeting Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, and Neisseria meningitidis. Highlights include:
Conjugate H. influenzae Type b (Hib) Vaccine:
Universal immunization programs have nearly eliminated Hib meningitis, though non-b serotypes like type a are emerging.
Vaccines for non-b serotypes are not yet available.
Conjugate Pneumococcal Vaccines:
Recommended for all infants and shown to be >95% effective against invasive diseases caused by the serotypes in the 7-valent vaccine.
The newer 13-valent vaccine has expanded coverage and reduced meningitis cases further.
High-risk individuals over 2 years old, including adults, may require both the conjugate and 23-valent polysaccharide vaccines.
Conjugate Meningococcal Vaccines:
Type C vaccines provide >90% efficacy and are routinely administered to infants.
Quadrivalent vaccines covering serotypes A, C, W, and Y are recommended for individuals over 2 years old or specific high-risk groups, including travelers to high-risk areas (e.g., sub-Saharan Africa, Hajj pilgrims).
High-risk patients, such as those receiving eculizumab, should receive both the quadrivalent vaccine and meningococcal B vaccines.
Meningococcal B Vaccines:
Multicomponent vaccines (e.g., 4CMenB) are available for individuals aged 2 months to 17 years. While not routinely recommended, they are advised for high-risk groups (e.g., asplenia, sickle cell disease) and outbreak management.
Another option, MenB-fHBP, is available for individuals aged 10 years and older.